Literature DB >> 2418164

An Eastern Cooperative Oncology Group phase I-II pilot study of polyriboinosinic-polyribocytidylic acid poly-L-lysine complex in patients with metastatic malignant melanoma.

M J Hawkins, M Levin, E C Borden.   

Abstract

Sixteen patients with metastatic malignant melanoma were treated with poly(I,C)-LC 5 mg/m2 twice weekly by intravenous injection. No antitumor responses occurred. Fever (frequently greater than 40 degrees C) and fatigue were dose limiting toxicities. One patient developed a fever of 42.2 degrees C when poly(I,C)-LC was given on 2 consecutive days. Interferon was consistently detected in the serum 8 h after a single injection of poly(I,C)-LC (median titer 199 U/ml). No enhancement of interferon induction was detected on the second day when poly(I,C)-LC was given on 2 consecutive days.

Entities:  

Mesh：

Substances：

Year:  1985        PMID： 2418164

Source DB:  PubMed          Journal:  J Biol Response Mod        ISSN： 0732-6580


  12 in total

Review 1.  Toll-like receptor agonists in cancer therapy.

Authors:  Sylvia Adams
Journal:  Immunotherapy       Date:  2009-11       Impact factor: 4.196

Review 2.  Toll-like receptor agonists: are they good adjuvants?

Authors:  Sacha Gnjatic; Nikhil B Sawhney; Nina Bhardwaj
Journal:  Cancer J       Date:  2010 Jul-Aug       Impact factor: 3.360

Review 3.  TLR-based immune adjuvants.

Authors:  Folkert Steinhagen; Takeshi Kinjo; Christian Bode; Dennis M Klinman
Journal:  Vaccine       Date:  2010-08-14       Impact factor: 3.641

4.  A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas.

Authors:  Nicholas Butowski; Kathleen R Lamborn; Bee L Lee; Michael D Prados; Timothy Cloughesy; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Frank Lieberman; Minesh Mehta; H Ian Robins; Larry Junck; Andres M Salazar; Susan M Chang
Journal:  J Neurooncol       Date:  2008-10-11       Impact factor: 4.130

Review 5.  TLR agonists: our best frenemy in cancer immunotherapy.

Authors:  Sabina Kaczanowska; Ann Mary Joseph; Eduardo Davila
Journal:  J Leukoc Biol       Date:  2013-03-08       Impact factor: 4.962

6.  A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05).

Authors:  Nicholas Butowski; Susan M Chang; Larry Junck; Lisa M DeAngelis; Lauren Abrey; Karen Fink; Tim Cloughesy; Kathleen R Lamborn; Andres M Salazar; Michael D Prados
Journal:  J Neurooncol       Date:  2008-09-17       Impact factor: 4.130

7.  TLR3 agonists and proinflammatory antitumor activities.

Authors:  Sherven Sharma; Li Zhu; Michael Davoodi; Marni Harris-White; Jay M Lee; Maie St John; Ravi Salgia; Steven Dubinett
Journal:  Expert Opin Ther Targets       Date:  2013-03-19       Impact factor: 6.902

8.  Trial Watch: Experimental Toll-like receptor agonists for cancer therapy.

Authors:  Lorenzo Galluzzi; Erika Vacchelli; Alexander Eggermont; Wolf Hervé Fridman; Jerome Galon; Catherine Sautès-Fridman; Eric Tartour; Laurence Zitvogel; Guido Kroemer
Journal:  Oncoimmunology       Date:  2012-08-01       Impact factor: 8.110

9.  Broad-spectrum drugs against viral agents.

Authors:  Mary E Christopher; Jonathan P Wong
Journal:  Int J Mol Sci       Date:  2008-09-01       Impact factor: 6.208

10.  Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients.

Authors:  Valerie Chew; Charlene Tow; Caleb Huang; Emilie Bard-Chapeau; Neal G Copeland; Nancy A Jenkins; Achim Weber; Kiat Hon Lim; Han Chong Toh; Mathias Heikenwalder; Irene Oi-Lin Ng; Alessandra Nardin; Jean-Pierre Abastado
Journal:  J Natl Cancer Inst       Date:  2012-11-29       Impact factor: 13.506
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.